Pharmaceuticals & Biotechnology

Beyond the Clinical Unmet Needs
Home Life Sciences Pharmaceuticals & Biotechnology

Pharma and Biotech industry segment is taking revolutionary measures on multiple fronts such as speed to market, value-based care, increase R&D productivity and the likelihood of success, lifecycle management, and preventive therapies for chronic diseases.  These measures are backed by technology advancements, digitalization, external collaboration, machine learning, and open innovation.

FutureBridge equips companies to take scientifically backed decisions for 5-25 years strategic horizon. This includes a high-level overview about evolving business models, disruptions resulting in materialistic change, or focused clinical and commercial questions addressing problems related to a sub-therapy area, sub-indication, or at disease level.

Decentralization, Automation, and Single-Use Technology – Future of Cell & Gene Therapy Manufacturing

Life Sciences

As the biopharmaceutical industry shifts its focus toward cell and gene therapies, the manufacturing landscape presents both opportunities and challenges. While regulatory approvals have enabled the industry to make strides in disease treatment, there is an ongoing...

Evolving New Opportunities – Bioprinting Industry

Life Sciences

There is an enormous and growing need for an alternative solution to the long waiting lists for organ transplantation and better human-relevant drug testing models. The production of artificial organs for transplantation would solve these issues of high demand and low...

Innovations in Navigation and Imaging Technologies - Shaping the Future of Surgery

Innovations in Navigation and Imaging Technologies – Shaping the Future of Surgery

Life Sciences

Non-invasive (NI) and minimally invasive (MI) surgical procedures are accomplished through sophisticated and flexible small tubes, tiny cameras, and surgical instruments, with less damage to the body than with open surgery. Medical fraternities have joined hands with...

Strategic Growth Fields

A convergence of industry transformations and exponential technologies creates a pool of opportunities

Paradigm Shift in

  • Shared risks & costs
  • Virtual clinical trials
  • Pipeline portfolio optimization
  • Lifecycle management

Personalization &
Drug Precision

  • Gene editing
  • Theragnostics
  • Biomarkers & generic diagnosis
  • Targeted drug delivery


  • Prevention & prophylaxis
  • Screening & early detection
  • Wellness & alternative therapies
  • Digital disease advocacy


  • Novel business models
  • Reimbursements & regulations
  • Patient centricity
  • Global demographical dynamics
Exponential Digital Technologies
  • Sustainability 85% 85%
  • Digitalization 94% 94%
  • Business Model Innovation 87% 87%
  • Synthetic Biology 92% 92%
  • Big Data & Clinical Algorithms 85% 85%

Business Objectives

Some examples of diverse business objectives we have worked with our clients

Strategy & Futures

  • Which opportunities should be prioritized to fill the gaps in the existing product portfolio?
  • How can we re-program the Onco-clinical development to be ahead in the competition?
  • What are the challenges faced by corporations to implement platforms related to augmented clinical trials?
  • Which are the low-hanging fruits with a high entry of barriers for competitors in Hematology?

Innovation, R&D & Clinical Development

  • How are companies leveraging rare disease product development?
  • What is the R&D roadmap of competitors for their key assets?
  • Where will regulations close or open my markets for novel ingredients?
  • What is the current state of technology of genomics for immuno-compromised patients?

Growth & Market Development

  • Where will unmet needs be within medical affairs?
  • How are companies actively engaging with new routes across different stakeholders?
  • What are the key patient trends? How will it impact my business?
  • Which geographies can be prioritized to enable ease of entry’ for orphan indications such as whiplash, trigeminal pain & RA?

Clinical Outcome and Patient Journey

  • What are the upcoming solutions to predict & measure clinical outcomes and how is it going to impact the patient journey in the future?
  • What is the KOL’s perspective on the adoption and safety of digital pills?
  • Which are the therapy areas that have been assessed for value-based treatment?
  • How patient-centric clinical trials and R&D would shape up in long term with EPR development?

Client's Success Stories

Life Sciences

Opportunity Assessment for Targeted Therapy– Anti PD-1/PDL-1 Therapy
With significant R&D community interest to explore targeted checkpoint inhibitors and understand continuous innovations, a top 10 pharma giant approached FutureBridge to conduct an in-depth study to identify the biomarkers, clinical efficacy, and toxicity of the...

Life Sciences

Selection of Breakthrough Technology & Suitable Partner – Gene Editing Platforms
A leading US pharmaceutical company was interested to understand the best in the class technology landscape in the Gene editing platforms for portfolio expansion. FutureBridge consulting team worked along with the portfolio function and developed a robust toolkit to...